Crinetics Pharmaceuticals IncNASDAQ:CRNX
- LAST PRICE55.9800
- TODAY'S CHANGE (%)-3.6800 (-6.1683%)
- Bid / Lots55.8900/ 6
- Ask / Lots56.0700/ 6
- Open / Previous Close60.1300 / 59.6600
- Day Range
- 52 Week Range
- Volume325,523
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRNX |
|---|---|---|
| 09:32 ET | 22892 | 59.84 |
| 09:33 ET | 844 | 60.1 |
| 09:35 ET | 1300 | 60.12 |
| 09:37 ET | 1000 | 59.51 |
| 09:39 ET | 200 | 59.21 |
| 09:42 ET | 500 | 58.8 |
| 09:44 ET | 3995 | 58.74 |
| 09:46 ET | 3241 | 58.3 |
| 09:48 ET | 1740 | 57.921 |
| 09:50 ET | 2958 | 57.94 |
| 09:51 ET | 2075 | 58 |
| 09:53 ET | 1936 | 58.61 |
| 09:55 ET | 200 | 58.55 |
| 09:57 ET | 300 | 58.395 |
| 10:00 ET | 400 | 58.445 |
| 10:02 ET | 3395 | 58.38 |
| 10:04 ET | 100 | 58.38 |
| 10:06 ET | 300 | 58.06 |
| 10:08 ET | 2104 | 57.74 |
| 10:09 ET | 23612 | 57.04 |
| 10:11 ET | 5694 | 57.54 |
| 10:13 ET | 1509 | 57.31 |
| 10:15 ET | 739 | 57.53 |
| 10:18 ET | 1101 | 57.34 |
| 10:20 ET | 900 | 57.33 |
| 10:22 ET | 1100 | 57.36 |
| 10:24 ET | 1000 | 57.13 |
| 10:26 ET | 3042 | 57.0931 |
| 10:27 ET | 400 | 57.29 |
| 10:29 ET | 1723 | 57.38 |
| 10:31 ET | 7300 | 57.22 |
| 10:33 ET | 1783 | 57.23 |
| 10:36 ET | 100 | 56.96 |
| 10:38 ET | 1200 | 56.71 |
| 10:40 ET | 1912 | 57.055 |
| 10:42 ET | 2049 | 56.83 |
| 10:44 ET | 955 | 56.885 |
| 10:45 ET | 940 | 56.87 |
| 10:47 ET | 640 | 56.785 |
| 10:49 ET | 720 | 56.825 |
| 10:51 ET | 2170 | 56.94 |
| 10:54 ET | 2404 | 56.65 |
| 10:56 ET | 7920 | 56.62 |
| 10:58 ET | 4709 | 56.55 |
| 11:00 ET | 7060 | 56.675 |
| 11:02 ET | 10336 | 56.255 |
| 11:03 ET | 1595 | 56.41 |
| 11:05 ET | 1020 | 56.24 |
| 11:07 ET | 1002 | 56.415 |
| 11:09 ET | 912 | 56.47 |
| 11:12 ET | 500 | 56.38 |
| 11:14 ET | 3600 | 56.21 |
| 11:16 ET | 4257 | 56.26 |
| 11:18 ET | 19957 | 56.385 |
| 11:20 ET | 800 | 56.195 |
| 11:21 ET | 1000 | 56.01 |
| 11:23 ET | 3853 | 56.36 |
| 11:25 ET | 7922 | 56.39 |
| 11:27 ET | 800 | 56.245 |
| 11:30 ET | 700 | 56.06 |
| 11:32 ET | 1150 | 55.86 |
| 11:34 ET | 300 | 55.86 |
| 11:36 ET | 1500 | 55.87 |
| 11:38 ET | 4824 | 55.59 |
| 11:39 ET | 9059 | 55.89 |
| 11:41 ET | 400 | 55.86 |
| 11:43 ET | 3599 | 55.905 |
| 11:45 ET | 100 | 55.99 |
| 11:48 ET | 3800 | 55.77 |
| 11:50 ET | 300 | 55.705 |
| 11:52 ET | 4333 | 56.03 |
| 11:54 ET | 1278 | 55.98 |
Today
Yesterday
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting, from 20 hours ago by Dow Jones
20 hours ago by Dow JonesDJ Crinetics Pharmaceuticals Is Maintained at Buy by Citigroup, from 22 hours ago by Dow Jones
22 hours ago by Dow Jones
Nov 13, 2024
DJ Crinetics Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co., from 1:57PM ET on Wednesday Nov 13, 2024 by Dow Jones
1:57PM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Crinetics Pharmaceuticals Inc | 5.3B | -15.1x | --- |
Krystal Biotech Inc | 5.1B | 97.0x | --- |
Biohaven Ltd | 4.8B | -5.0x | --- |
Nuvalent Inc | 5.9B | -25.7x | --- |
Avidity Biosciences Inc | 5.9B | -15.6x | --- |
Viking Therapeutics Inc | 6.0B | -54.2x | --- |
Company Information
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Contact Information
- Headquarters
- 10222 Barnes Canyon Rd Bldg 2SAN DIEGO, CA, United States 92121-2711
- Phone
- 858-450-6464
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Wendell Wierenga
- President, Chief Executive Officer, Co-Founder, Director
- R. Scott Struthers
- Co-Founder, Chief Scientific Officer
- Stephen Betz
- Chief Financial Officer
- Marc Wilson
- Chief Operating Officer
- Jeff Knight
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.3B |
|---|---|
Revenue (TTM) | $1.0M |
Shares Outstanding | 89.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.61 |
EPS | $-3.72 |
Book Value | $7.91 |
P/E Ratio | -15.1x |
Price/Sales (TTM) | 5,129.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -29,525.22% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
